A Single-Site, Phase I/II, Double Blinded, Safety and Immunogenicity Trial of an Alphavirus Replicon Vaccine Expressing Influenza A/Wyoming/03/2003 Hemagglutinin (AVX502) in Adult Volunteers 65 Years of Age or Older
Phase of Trial: Phase I/II
Latest Information Update: 11 Jul 2012
At a glance
- Drugs AVX 502; AVX 502
- Indications Influenza virus infections
- Focus Adverse reactions
- 01 Mar 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Nov 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 25 Jul 2008 New trial record.